Beigene, Ltd. (NASDAQ:ONC) COO Xiaobin Wu Sells 51,921 Shares

Beigene, Ltd. (NASDAQ:ONC) COO Xiaobin Wu sold 51,921 shares of the business’s stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $281.40, for a total transaction of $14,610,569.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Xiaobin Wu also recently made the following trade(s):

• On Wednesday, March 5th, Xiaobin Wu sold 51,921 shares of Beigene stock. The shares were sold at an average price of $261.59, for a total transaction of $13,582,014.39.
• On Thursday, February 20th, Xiaobin Wu sold 21,267 shares of Beigene stock. The stock was sold at an average price of $240.07, for a total value of $5,105,568.69.
• On Tuesday, February 18th, Xiaobin Wu sold 30,654 shares of Beigene stock. The shares were sold at an average price of $240.74, for a total value of $7,379,643.96.

Beigene Stock Down 3.8 %

Shares of ONC stock traded down $10.46 during trading on Thursday, hitting $264.32. The company had a trading volume of 389,916 shares, compared to its average volume of 460,234. The stock has a market cap of $26.07 billion, a price-to-earnings ratio of -32.08, a price-to-earnings-growth ratio of 7.73 and a beta of 0.65. The company has a current ratio of 1.93, a quick ratio of 1.72 and a debt-to-equity ratio of 0.05. Beigene, Ltd. has a 52 week low of $126.97 and a 52 week high of $287.88.

Beigene (NASDAQ:ONC) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($1.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.55). Beigene had a negative return on equity of 25.12% and a negative net margin of 25.94%. The company had revenue of $1.13 billion during the quarter, compared to the consensus estimate of $1.09 billion. Sell-side analysts predict that Beigene, Ltd. will post -5.82 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on ONC shares. Sanford C. Bernstein set a $259.00 price objective on Beigene in a report on Thursday, March 13th. Guggenheim reissued a “buy” rating on shares of Beigene in a report on Friday, February 28th. Macquarie boosted their price objective on shares of Beigene from $259.00 to $313.00 and gave the company an “outperform” rating in a research note on Friday, February 28th. JMP Securities set a $348.00 target price on shares of Beigene in a research note on Friday, February 28th. Finally, Bank of America upgraded shares of Beigene from a “neutral” rating to a “buy” rating and boosted their price target for the company from $207.00 to $320.00 in a research report on Monday, March 3rd.

About Beigene

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.